Browse drugs

…tients (10 injections); faricimab 94 patients (321 injections); ranibizumab 37 patients (127 injections).Classified by most frequent diagno…

…III randomised controlled trials (RCTs) evaluating ranibizumab, brolucizumab, aflibercept, and faricimab in nAMD. Baseline characteristics i…

…ain—ranibizumab, aflibercept (2 mg and 8 mg), brolucizumab, and faricimab—each differing in dosing interval, mechanism, and cost. Compara…

…used significant vision loss and substantial treatment burdens. Brolucizumab is a new-generation anti-VEGF agent with better anatomical effi…

…nterval with the anti-vascular endothelial growth factor (VEGF) brolucizumab in the loading phase may reduce treatment burden while maintain…

…otal of 3,223 patients received 31,826 intravitreal injections. Bevacizumab was the most frequently prescribed drug (58.73%, n=18,690), fol…

…tervals than with previous anti-VEGF therapies, indicating that faricimab is effective for individualised dosing in real-world settings. …

…th IMU. Among 117 drugs with positive signals for IMU in FAERS, brolucizumab (ROR 025=145.89, IC025=7.08), faricimab (ROR025=134.06, IC025=6…

… and biosimilar ranibizumab, aflibercept 2 mg, brolucizumab and faricimab—across three dosing regimens: fixed, Pro Re Nata and Treat-and-…